Development of the tests – initially for Clostridium difficile and Helicobacter pylori - will be conducted by Meridian Bioscience, Inc. (Cincinnati, OH, USA). The test format will be dedicated for use on the DiaSorin (Saluggia, Italy) LIAISON system. LIAISON is a fully automated, random access system based on chemiluminescense detection, which will soon be augmented by the introduction of the new high-throughput LIAISON XL model.

Under the agreement with Meridian, DiaSorin will have exclusive distribution rights for the developed products in every geographic market except the United States and United Kingdom, where Meridian will retain the option for distribution.

John A. Kraeutler, CEO of Meridian said, "We value this collaboration with DiaSorin and we are encouraged by the prospect of expanding the reach for Meridian's infectious disease technologies. DiaSorin has a very large base of installed LIAISON systems around the world and this agreement provides Meridian access to new markets and new customers through those placements. We pride ourselves on being able to offer our customer base a variety of platforms to meet their specific needs and now we can provide a fully automated system option through this new partnership with DiaSorin.”

Carlo Rosa, CEO of DiaSorin, stated, "We are sincerely happy with this agreement that will give us the opportunity to partner with Meridian, a leading company in GI tract infections. 3,000 LIAISON platforms installed worldwide, covering almost all geographical areas, combined with a menu enriched by high quality tests developed with Meridian will definitely enable our Group to underscore, even more unequivocally, its position as a specialist in the area of infectious diseases.”

Related Links:
Meridian Bioscience, Inc.
DiaSorin